Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
New WHO INN for cell-based and gene-based substances: timing, usage, and simplicity.
Journal: Lancet (London, England)
Published: August 29, 2024
Association between benzodiazepine coprescription and mortality in people on opioid replacement therapy: a population-based cohort study.
Journal: BMJ open
Published: March 14, 2024
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Journal: Vaccine
Published: January 19, 2022
International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
Journal: Vaccine
Published: June 02, 2021
The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough.
Journal: Cytotherapy
Published: January 28, 2021
WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
Journal: Lancet (London, England)
Published: January 08, 2021
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Journal: Vaccine
Published: August 28, 2020
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Journal: Vaccine
Published: August 13, 2020
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Journal: Vaccine
Published: July 27, 2020
Last Updated: 09/26/2026